Targeted Therapies in Oncology

September II, 2024
Volume: 13
Issue: 12

September I, 2024
Volume: 13
Issue: 11

August I, 2024
Volume: 13
Issue: 10

July I, 2024
Volume: 13
Issue: 9

June 02, 2024
Volume: 13
Issue: 8

June I, 2024
Volume: 13
Issue: 7

May I, 2024
Volume: 13
Issue: 6

April I, 2024
Volume: 13
Issue: 5

March II, 2024
Volume: 13
Issue: 4

March I, 2024
Volume: 13
Issue: 3

February I, 2024
Volume: 13
Issue: 2

January I, 2024
Volume: 13
Issue: 1

December II, 2023
Volume: 12
Issue: 18

December I, 2023
Volume: 12
Issue: 17

November II, 2023
Volume: 12
Issue: 16

November I, 2023
Volume: 12
Issue: 15

October II, 2023
Volume: 12
Issue: 14

October I
Volume: 12
Issue: 13

September I
Volume: 12
Issue: 12

August I
Volume: 12
Issue: 11

July 1, 2023
Volume: 12
Issue: 9

July II, 2023
Volume: 12
Issue: 10

June 2023
Volume: 12
Issue: 8

May 2023
Volume: 12
Issue: 7

April 2, 2023
Volume: 12
Issue: 6

April 1, 2023
Volume: 12
Issue: 5

March 1, 2023
Volume: 12
Issue: 3

February 2023
Volume: 12
Issue: 2

January 2023
Volume: 11
Issue: 17

December 2, 2022
Volume: 11
Issue: 18
Advertisement
Advertisement
Trending on Targeted Onc
1
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
2
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
3
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
4
Oncologists Weigh Age and Drug Interactions in mHSPC Treatment Selection
5
